Novo Nordisk A/S (ADR) (NYSE:NVO) plunged -0.22% during previous trade, a total of 3.98M shares exchanged hands compared with its average trading volume of 3.48M shares whereas its relative volume is 1.19. The stock has a market capitalization of $80.39B along with 1.96B outstanding shares. Stock’s intraday price range hit the peak level of $40.62 and touched the lowest level of $40.11.

Most recently Novo Nordisk A/S (ADR) (NYSE:NVO)’s price target was revised on 10/21/16 and according to 1 analyst stock’s price will reach at $57 during 52 weeks with standard deviation of 57. Stock’s minimum price target estimates has been figured out at $57 while the maximum price target forecast is established at $57, if we look at the price target with an optimistic approach it has upside potential of 56% from its latest closing price of $40.24.

Historically, if we look at price target revisions, two weeks ago Novo Nordisk A/S (ADR) (NYSE:NVO)’s price target was revised on 09/8/16 by the analysts, however the bullish price estimates of the stock set at $57 while the bearish estimates kept at $57 over the next one year. Stock’s 52-week target was retained at $57, the estimates indicates a standard deviation of 57.

While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 3. ABR value is precisely based on brokerage recommendations, where out of 3 brokerage recommendations 0 rate Novo Nordisk A/S (ADR) (NYSE:NVO) stock a Strong Buy, 0 rate the stocks of the company a Buy, 3 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 9/13/16 the stock of Novo Nordisk A/S (ADR) (NYSE:NVO) upgraded by Exane BNP Paribas from Neutral to Outperform. However previously on 9/9/16 it was downgraded by JP Morgan from Overweight to Neutral. A research note issued on 9/1/16 the stock was downgraded by Morgan Stanley from Overweight to Equal-Weight.

Novo Nordisk A/S (ADR) (NYSE:NVO) performance over the past one year plunged -26.23% whereas its year to date (YTD) performance indicated a bullish/bearish trend of -28.82%. During the last six months the stock slipped -27.51%. Quarterly performance of the company shows declining momentum of -28.15% while its last one month trend is negative with -8.23%. Stock’s weekly performance expressed down trend of -0.62%.

The company’s price sits -8.63% below from its 50-day moving average of $42.76 and -20.98% below from the stock’s 200-day moving average which is $50.55. Novo Nordisk A/S (ADR) (NYSE:NVO)’s shares are currently trading -29.93% away from the 52-week high price of $57.43 and +3.10% far from the 52-week low price of $39.03.

According to consensus agreement of 1 analyst Novo Nordisk A/S (ADR) (NYSE:NVO) will report earnings per share of $0.56 in their quarterly report and it is expected to announce the company’s results on 10/28/16 Before Market Open. For the current quarter the company has high EPS estimates of $0.56 in contradiction of low EPS estimates of $0.56. However a year ago for the same quarter the company has reported $0.49 EPS. Current year EPS projections for Novo Nordisk A/S (ADR) (NYSE:NVO) set at $2.22 according to the sentiments of 2 analysts, while its lowest earnings estimates are $2.21 and highest earnings estimates are $2.22.

According to 1 analyst, Novo Nordisk A/S (ADR) (NYSE:NVO)’s revenue estimates for the current quarter are $4.12B meanwhile the company has high revenue estimates of $4.12B in contradiction of low revenue estimates of $4.12B. For the current year the company’s revenue estimates are $16.28B compared to low analyst estimates of $16.16B and high estimates of $16.41B according to the projection of 2 analysts.